David Knorr
Family Medicine · Palmyra, MONPI 1255310850
Payments from drug & device makers
Across 220 payments — averaging $14.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$913
- AstraZeneca$468
- Otsuka America Pharmaceutical, Inc.$288
- Novo Nordisk$219
- Amgen$211
- Novartis$197
- plus $956 from 21 others
What the payments were for
- Food & beverage$3,253100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 87 | $913 |
| AstraZeneca | 24 | $468 |
| Otsuka America Pharmaceutical, Inc. | 15 | $288 |
| Novo Nordisk | 18 | $219 |
| Amgen | 12 | $211 |
| Novartis | 11 | $197 |
| Lilly USA, LLC | 8 | $139 |
| Boehringer Ingelheim | 6 | $104 |
| Teva Pharmaceuticals USA, Inc. | 3 | $77 |
| Pfizer | 5 | $74 |
| Axsome Therapeutics, Inc. | 4 | $61 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $60 |
| Nestle Healthcare Nutrition Inc. | 1 | $43 |
| Exact Sciences | 2 | $40 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Lundbeck LLC | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 2 | $36 |
| Gilead | 2 | $35 |
| Sumitomo Pharma America, Inc. | 3 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Harmony Biosciences LLC | 2 | $30 |
| Corium, LLC | 1 | $30 |
| Corcept Therapeutics | 1 | $24 |
| Vertex | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $14 |
How this compares
$3,253 in reported general payments places this provider in the 80th percentile of 2,203 family medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 102 | $119,643 |
| EliquisApixaban | 156 | $101,331 |
| MounjaroTirzepatide | 63 | $75,915 |
| FarxigaDapagliflozin Propanediol | 74 | $61,392 |
| JardianceEmpagliflozin | 55 | $51,633 |
| TrulicityDulaglutide | 51 | $49,571 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 67 | $35,808 |
| RexultiBrexpiprazole | 32 | $32,446 |
| JanuviaSitagliptin Phosphate | 54 | $26,276 |
| XareltoRivaroxaban | 28 | $24,513 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $24,222 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 543 | $21,151 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $18,522 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $17,743 |
| RybelsusSemaglutide | 18 | $16,622 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $219 | $136,265120 claims |
| Lilly USA, LLCMounjaro, Trulicity | $139 | $125,486114 claims |
| PfizerEliquis, Abrysvo | $74 | $109,581184 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat | $104 | $97,083138 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $468 | $92,471131 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $288 | $32,44632 claims |
| AbbVieVraylar, Linzess | $913 | $14,78323 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $31 | $7,62022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Palmyra
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.